A QS21+ CpG‐Adjuvanted Inactivated Vaccine Elicits Superior Humoral and Moderate Cellular Immunity
Journal of Medical Virology · 2026
DOI: 10.1002/jmv.71179 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2026. Verfasst von Han Cao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming, Yunnan, China. Hauptthemen laut MEDLINE: Rabies Vaccines, Immunity, Humoral, Immunity, Cellular, Adjuvants, Immunologic. Die Arbeit nennt 20 Literaturangaben. Gefördert von: Yunnan Fundamental Research Projects, the Special Biomedicine Projects of Yunnan Province, the Funds for the Training of High-level Health Technical Personnel in Yunnan Province.
Abstract (Originalsprache)
Rabies remains a fatal zoonotic disease caused by rabies virus (RABV), posing substantial global health challenges. Current vaccine production faces challenges in manufacturing efficiency and cost‐effectiveness. Inactivated vaccines without any adjuvants are the sole vaccines licensed for the prophylaxis of rabies. We developed a novel QS21+CpG‐adjuvanted inactivated vaccine and systematically compared its performance against inactivated vaccine and Alum‐adjuvanted inactivated vaccine. The result shows the QS21+CpG‐adjuvanted inactivated vaccine elicited superior humoral immunity, as evidenced by significantly higher RABV‐specific IgG titers and virus‐neutralizing antibody responses compared to all other groups. The QS21+CpG‐adjuvanted inactivated vaccine maintained its expected cellular immunity advantage, with significantly increased frequencies of IFN‐γ‐ and IL‐2‐secreting splenocytes, as well as elevated IFN‐γ and IL‐2 levels in splenocyte culture supernatants. Both QS21+CpG and Alum‐adjuvanted inactivated vaccine groups provided 100% protection against lethal challenge. These findings provide novel adjuvant strategies for licensed inactivated rabies vaccines and offer critical insights for pathogens requiring robust humoral and Th1‐biased cellular immunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming, Yunnan, China.
ORCID-Profile: Ning Luan, Jie Song, Cunbao Liu
Förderung
- Yunnan Fundamental Research Projects
- the Special Biomedicine Projects of Yunnan Province
- the Funds for the Training of High-level Health Technical Personnel in Yunnan Province
Zitieren
APA
Cao, H., Li, H., Yin, A., Luan, N., Jia, C., Song, J., & Liu, C. (2026). A QS21+ CpG‐Adjuvanted Inactivated Vaccine Elicits Superior Humoral and Moderate Cellular Immunity. Journal of Medical Virology. https://doi.org/10.1002/jmv.71179
Vancouver
Cao H, Li H, Yin A, Luan N, Jia C, Song J, et al. A QS21+ CpG‐Adjuvanted Inactivated Vaccine Elicits Superior Humoral and Moderate Cellular Immunity. Journal of Medical Virology. 2026. doi:10.1002/jmv.71179
BibTeX
@article{Cao2026,
author = {Cao, Han and Li, Hui and Yin, Anguo and Luan, Ning and Jia, Chenxi and Song, Jie and Liu, Cunbao},
title = {A QS21+ CpG‐Adjuvanted Inactivated Vaccine Elicits Superior Humoral and Moderate Cellular Immunity},
journal = {Journal of Medical Virology},
year = {2026},
doi = {10.1002/jmv.71179}
}
EUVIMED